Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
Okamoto
M
M
Okano
A
A
Akamatsu
S
S
Ashihara
E
E
Inaba
T
T
Takenaka
H
H
Katoh
N
N
Kishimoto
S
S
Shimazaki
C
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D012307:Risk Factors; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013256:Steroids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D013256:Steroids; D000069283:Rituximab